Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Amniotics
Lund, Swedenamniotics.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
01
Overview
Amniotics has completed GMP process validation and entered clinical phase with its lead candidate PulmoStem™, a first-in-class cell therapy targeting severe pulmonary disease. The company’s unique approach leverages neonatal-quality MSCs derived from full-term amniotic fluid. Early-stage results focus on safety and feasibility; efficacy data pending as trials progress. Additional candidates are in preclinical development across multiple organ systems.
- Therapeutic areas
- PulmonologyOther
- Modalities
- Stem cell therapyCell therapyAdvanced Therapy Medicinal ProductBiologic
- Industry
- Biotech
02
Partnerships
Strategic partnerships sought with researchers/universities/hospitals/pharma companies interested in ATMP development; no major pharma partnership publicly disclosed yet
Beyond the preview
Go deeper on Amniotics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amniotics.